fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Triple-drug therapy safely cuts serious asthma flares

Written by | 25 May 2021

Researchers have found that the inclusion of a third drug to commonly used dual-drug inhalers can reduce asthma exacerbations and improve control over the disease in children, adolescents,… read more.

The problems with polypharmacy

Written by | 12 May 2021

Interview and article by Christine Clark Polypharmacy, or the concomitant use of multiple medicines, is estimated to cost $18 billion and account for 8.6 million hospital admissions annually… read more.

EU gives green light for new medicines

Written by | 12 May 2021

Article written by Gary Finnegan. The European Medicines Agency’s (EMA) key committee, known as the CHMP, has recommended approval of eight medicines at its latest meeting. While the… read more.

EMA backs six new medicines

Written by | 14 Mar 2021

Article written by Gary Finnegan. The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six medicines for approval at its February 2021 meeting:

EU watchdog approves 10 new drugs

Written by | 3 Dec 2020

Article written by Gary Finnegan. The European Medicines Agency (EMA) has given the green light for ten new medicines at the latest meeting of its influential Committee for… read more.

Have Pharma gone Webinar crazy!?

Written by | 19 Aug 2020

Article written by Peter Mas-Mollinedo With the outbreak of the Pandemic and the lingering worries of COVID-19 pharmaceutical sales and marketing has taken a hit. There are no… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.